Viral Vector Manufacturing Global Market Report 2024

Description

Viral vector manufacturing involves the creation of viral vectors, tools designed to transport genetic material into cells. These vectors serve as carriers for gene transfer, enabling specific cell types or tissues to express therapeutic genes.

The primary categories of viral vector manufacturing include adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and other variations. Adenoviral vectors, for instance, are double-stranded DNA vectors lacking an outer casing. These vectors find application across a spectrum of diseases including cancer, genetic disorders, infectious diseases, and more, utilizing workflows involving both upstream and downstream processing. These technologies have diverse applications in gene and cell therapy development, vaccine research, and the discovery phases of biopharmaceuticals and pharmaceuticals. They are extensively utilized in research institutions, biotechnology and pharmaceutical companies, and various other related fields for biomedical research purposes.

The viral vector manufacturing market research report is one of a series of new reports from The Business Research Company that provides viral vector manufacturing market statistics, including viral vector manufacturing industry global market size, regional shares, competitors with a viral vector manufacturing market share, detailed viral vector manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector manufacturing industry. This viral vector manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral vector manufacturing market size has grown exponentially in recent years. It will grow from $5.82 billion in 2023 to $7 billion in 2024 at a compound annual growth rate (CAGR) of 20.4%. The growth observed during the historic period can be attributed to several factors, including the expansion of the gene therapy pipeline, notable clinical successes leading to approvals, heightened investments in biopharmaceuticals, and the rising prevalence of genetic disorders. These factors collectively contributed to the growth and advancement of viral vector manufacturing within the biopharmaceutical industry.

The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $14.55 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The anticipated growth in the forecast period can be attributed to several factors, notably the widening applications of viral vectors in oncology, increased global collaborations within gene therapy research, the adoption of viral vectors in vaccine development, and the ongoing progress in clinical trials leading to commercialization efforts. Key trends expected in this period encompass technological innovations focused on enhancing vector production methods, the emergence of next-generation vectors with improved capabilities, efforts towards regulatory compliance and standardization within the industry, increased collaborations and partnerships among stakeholders, and the global expansion of manufacturing facilities to meet growing demands in the viral vector manufacturing landscape.

The rise in the prevalence of cancer and infectious diseases is anticipated to be a significant driver for the growth of the viral vector manufacturing market. Infectious diseases, transmitted through contact with infected individuals, animals, or objects, are caused by viruses or their toxic byproducts. Cancer, characterized by abnormal cell growth, invasion of neighboring organs, and potential spread to other parts of the body, is a diverse group of diseases. Viral vectors play a crucial role in cancer treatment by producing tumor antigens-proteins on tumor cells that trigger the body's anticancer immune response. Additionally, viral vectors have been utilized in pre-clinical and clinical trials as vaccines against various infectious diseases. According to the World Health Organization, there were 247 million cases of malaria in 2021, compared to 245 million cases in 2020. The Centers for Disease Control and Prevention reported 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US in 2020. This increase in the prevalence of cancer and infectious diseases is a key factor driving the growth of the viral vector manufacturing market.

The growth of the viral vector manufacturing market is further propelled by the expanding pipeline of gene therapy. Gene therapy involves manipulating or replacing genetic material within an individual's cells to treat or prevent diseases. Viral vector manufacturing plays a crucial role in this domain by providing efficient and scalable platforms for producing viral vectors, which serve as vital vehicles for delivering therapeutic genes into target cells. This advancement facilitates the development of innovative gene therapies. In January 2023, the American Society of Gene & Cell Therapy reported a 7% growth in the US gene, cell, and RNA therapy pipeline in 2022, totaling 3,726 therapies. The preclinical stage dominates with 70% of therapies, and oncology leads as the most active therapeutic area, hosting over 1,300 gene and cell therapy candidates. The expanding pipeline of gene therapy is a driving force behind the growth of the viral vector manufacturing market.

Product innovation is a prominent trend in the viral vector manufacturing market, with major companies introducing advanced solutions to maintain and strengthen their positions. In August 2022, Merck KGaA, a German-based science and technology company, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. As one of the first Contract Development and Manufacturing Organizations (CDMOs) and technology creators to provide a complete viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development, Merck KGaA addresses the need for a comprehensive solution in the industry. The VirusExpress 293 AAV Production Platform allows biopharmaceutical companies to streamline process development, reduce time and costs, and accelerate the timeline for clinical manufacture.

Major players in the viral vector manufacturing market are emphasizing the development of advanced products, particularly viral vector platforms tailored for efficient viral vector production and manufacturing. Viral vector platforms are comprehensive systems designed to streamline the production and processing of viral vectors for various applications, including gene therapy and vaccine development. In May 2023, AGC Biologics, a US-based global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), launched the BravoAAV and ProntoLVV platforms. These platforms are specifically designed to provide flexible and accelerated vector development and manufacturing for cell and gene therapy programs. Offering GMP product delivery in nine months, supported by a global regulatory and supply network, and in-house plasmid DNA services, these platforms play a crucial role in meeting the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines. Custom processes, templated material approaches, and prequalified analytical methods further contribute to the significance of these platforms in the viral vector manufacturing market, which is projected to reach $5.5 billion by 2035.

In January 2021, Thermo Fisher Scientific Inc., a leading US-based supplier of software, services, analytical tools, reagents and consumables, and medical equipment, completed the acquisition of Henogen S.A. for a total of $874.5 million. The strategic purpose behind this acquisition by Thermo Fisher Scientific Inc. is to enhance its global capacity for manufacturing cell and gene therapies as well as vaccines. Henogen S.A., based in Belgium, is a biomanufacturing company specializing in the production of viral vectors.

Major companies operating in the viral vector manufacturing market report are Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC,Oxford Biomedica plc, REGENXBIO Inc., LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

North America was the largest region in the viral vector manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The viral vector manufacturing market includes revenues earned by entities through the production, packaging, and labeling of viral vector vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Vector Manufacturing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral vector manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral vector manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral vector manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Adenoviral Vectors; Adeno-Associated Viral Vectors; Lentiviral Vectors; Retroviral Vectors; Other Types
2) By Disease: Cancer; Genetic Disorders; Infectious Diseases; Other Diseases
3) By Workflow: Upstream Processing; Downstream Processing
4) By Application: Gene And Cell Therapy Development; Vaccine Development; Biopharmaceutical And Pharmaceutical Discovery; Biomedical Research
5) By End-User: Research Organizations; Biotech And Pharmaceutical Companies; Others End Users
Companies Mentioned: Sanofi S.A.; Thermo Fisher Scientific Inc.; Merck Group; FUJIFILM Holdings Corporation; Lonza Group
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13920

1. Executive Summary

2. Viral Vector Manufacturing Market Characteristics

3. Viral Vector Manufacturing Market Trends And Strategies

4. Viral Vector Manufacturing Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Viral Vector Manufacturing Market Size and Growth

5.1. Global Viral Vector Manufacturing Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Viral Vector Manufacturing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Viral Vector Manufacturing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Viral Vector Manufacturing Market Segmentation

6.1. Global Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Adenoviral Vectors
Adeno-Associated Viral Vectors
Lentiviral Vectors
Retroviral Vectors
Other Types
6.2. Global Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
6.3. Global Viral Vector Manufacturing Market, Segmentation By Workflow, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Upstream Processing
Downstream Processing
6.4. Global Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Gene And Cell Therapy Development
Vaccine Development
Biopharmaceutical And Pharmaceutical Discovery
Biomedical Research
6.5. Global Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Research Organizations
Biotech And Pharmaceutical Companies
Others End Users

7. Viral Vector Manufacturing Market Regional And Country Analysis

7.1. Global Viral Vector Manufacturing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Viral Vector Manufacturing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Viral Vector Manufacturing Market

8.1. Asia-Pacific Viral Vector Manufacturing Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Viral Vector Manufacturing Market

9.1. China Viral Vector Manufacturing Market Overview
9.2. China Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Viral Vector Manufacturing Market

10.1. India Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Viral Vector Manufacturing Market

11.1. Japan Viral Vector Manufacturing Market Overview
11.2. Japan Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Viral Vector Manufacturing Market

12.1. Australia Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Viral Vector Manufacturing Market

13.1. Indonesia Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Viral Vector Manufacturing Market

14.1. South Korea Viral Vector Manufacturing Market Overview
14.2. South Korea Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Viral Vector Manufacturing Market

15.1. Western Europe Viral Vector Manufacturing Market Overview
15.2. Western Europe Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Viral Vector Manufacturing Market

16.1. UK Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Viral Vector Manufacturing Market

17.1. Germany Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Viral Vector Manufacturing Market

18.1. France Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Viral Vector Manufacturing Market

19.1. Italy Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Viral Vector Manufacturing Market

20.1. Spain Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Viral Vector Manufacturing Market

21.1. Eastern Europe Viral Vector Manufacturing Market Overview
21.2. Eastern Europe Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Viral Vector Manufacturing Market

22.1. Russia Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Viral Vector Manufacturing Market

23.1. North America Viral Vector Manufacturing Market Overview
23.2. North America Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Viral Vector Manufacturing Market

24.1. USA Viral Vector Manufacturing Market Overview
24.2. USA Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Viral Vector Manufacturing Market

25.1. Canada Viral Vector Manufacturing Market Overview
25.2. Canada Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Viral Vector Manufacturing Market

26.1. South America Viral Vector Manufacturing Market Overview
26.2. South America Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Viral Vector Manufacturing Market

27.1. Brazil Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Viral Vector Manufacturing Market

28.1. Middle East Viral Vector Manufacturing Market Overview
28.2. Middle East Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Viral Vector Manufacturing Market

29.1. Africa Viral Vector Manufacturing Market Overview
29.2. Africa Viral Vector Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Viral Vector Manufacturing Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Viral Vector Manufacturing Market Competitive Landscape And Company Profiles

30.1. Viral Vector Manufacturing Market Competitive Landscape
30.2. Viral Vector Manufacturing Market Company Profiles
- 30.2.1. Sanofi S.A.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Thermo Fisher Scientific Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck Group
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. FUJIFILM Holdings Corporation
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Lonza Group
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Viral Vector Manufacturing Market Other Major And Innovative Companies

31.1. Catalent Inc.
31.2. Sartorius AG
31.3. Charles River Laboratories International Inc.
31.4. AGC Biologics
31.5. Ultragenyx Pharmaceutical Inc.
31.6. Novasep Holding SAS
31.7. Aldevron LLC
31.8. Oxford Biomedica plc
31.9. REGENXBIO Inc.
31.10. LakePharma Inc.
31.11. Voyager Therapeutics Inc.
31.12. Mustang Bio Inc.
31.13. Regenxbio Inc.
31.14. VGXI Inc.
31.15. BioNTech IMFS GmbH

32. Global Viral Vector Manufacturing Market Competitive Benchmarking

33. Global Viral Vector Manufacturing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Viral Vector Manufacturing Market

35. Viral Vector Manufacturing Market Future Outlook and Potential Analysis

35.1 Viral Vector Manufacturing Market In 2028 - Countries Offering Most New Opportunities
35.2 Viral Vector Manufacturing Market In 2028 - Segments Offering Most New Opportunities
35.3 Viral Vector Manufacturing Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer